Medifast - MED . NYSE
Purchase Notes - September 2019
Medifast is a US-based multi-level marketer offering a comprehensive weight loss program through its network of home-based coaches. The company did a re-branding in 2016 and launched a new program under the name of OPTAVIA, backed up by a wide selection of specially formulated, nutritionally balanced, portion-controlled, convenience food products. The program has been a resounding success and has fueled extremely rapid growth since its launch 3 years ago. The company foresees additional growth in the future as it expands its network of coaches in the US and makes some initial forays into the potentially lucrative Asian market. With a trailing p:e of 17 at the current share price of $100.83, the company is not unreasonably priced considering its high growth trajectory. If this trajectory continues, the stock price should respond well.
What's changed since I made my first purchase of this stock? Follow the ongoing story in the posts below...